WO2007005716A3 - Methods of treatment and compositions for use thereof - Google Patents

Methods of treatment and compositions for use thereof Download PDF

Info

Publication number
WO2007005716A3
WO2007005716A3 PCT/US2006/025783 US2006025783W WO2007005716A3 WO 2007005716 A3 WO2007005716 A3 WO 2007005716A3 US 2006025783 W US2006025783 W US 2006025783W WO 2007005716 A3 WO2007005716 A3 WO 2007005716A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
treatment
levorphanol
compositions
directed
Prior art date
Application number
PCT/US2006/025783
Other languages
French (fr)
Other versions
WO2007005716A2 (en
Inventor
Najib Babul
Original Assignee
Cinergen Llc
Najib Babul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cinergen Llc, Najib Babul filed Critical Cinergen Llc
Publication of WO2007005716A2 publication Critical patent/WO2007005716A2/en
Publication of WO2007005716A3 publication Critical patent/WO2007005716A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention is directed to a method of treating or preventing pain in humans and lower animals which comprises administering concurrently to a human or lower animal in need of such treatment or prevention a μ-opioid agonist and levorphanol, wherein said concurrent administration produces an enhanced effect. The present invention is also directed to pharmaceutical compositions comprising a μ-opioid agonist and levorphanol useful for carrying out the method of the present invention.
PCT/US2006/025783 2005-06-30 2006-06-29 Methods of treatment and compositions for use thereof WO2007005716A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69497505P 2005-06-30 2005-06-30
US60/694,975 2005-06-30

Publications (2)

Publication Number Publication Date
WO2007005716A2 WO2007005716A2 (en) 2007-01-11
WO2007005716A3 true WO2007005716A3 (en) 2007-11-22

Family

ID=37605081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/025783 WO2007005716A2 (en) 2005-06-30 2006-06-29 Methods of treatment and compositions for use thereof

Country Status (1)

Country Link
WO (1) WO2007005716A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US8309060B2 (en) 2003-08-06 2012-11-13 Grunenthal Gmbh Abuse-proofed dosage form

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
MX2008014794A (en) * 2006-05-26 2009-04-08 Pharmacofore Inc Controlled release of phenolic opioids.
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
DE102007019417A1 (en) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol for the treatment of pain in osteoarthritis
MX360289B (en) * 2007-11-23 2018-10-29 Gruenenthal Gmbh Tapentadol compositions.
AU2009207796B2 (en) * 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
BRPI0912014A2 (en) 2008-05-09 2019-03-06 Grünenthal GmbH A process for preparing an intermediate powder formulation and a final solid dosage form using a spray freeze step
PT2331210E (en) * 2008-09-05 2014-08-25 Gruenenthal Gmbh Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
US20120065221A1 (en) * 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
RU2015138422A (en) 2009-07-22 2018-12-25 Грюненталь Гмбх STABLE DURING OXIDATION, STRONG-BREAKED DOSAGE FORM
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
PL2611426T3 (en) 2010-09-02 2014-09-30 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
EP2736497B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
TWI522101B (en) 2012-04-17 2016-02-21 普渡製藥有限合夥事業 Systems and methods for treating an opioid-induced adverse pharmacodynamic response
MX362357B (en) 2012-04-18 2019-01-14 Gruenenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096439A1 (en) 2013-05-29 2015-12-30 Gruenenthal Gmbh DOSAGE METHOD RESISTING TO INDEED USE CONTAINING ONE OR MORE PARTICLES
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EA032465B1 (en) 2013-07-12 2019-05-31 Грюненталь Гмбх Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof
CN105934241B (en) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 Preparation of powdered pharmaceutical composition by cryogenic grinding
JP2017518980A (en) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Anti-modification immediate release capsule formulation containing tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2018191472A1 (en) * 2017-04-14 2018-10-18 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310072B1 (en) * 1995-10-19 2001-10-30 The University Of Queensland Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310072B1 (en) * 1995-10-19 2001-10-30 The University Of Queensland Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORGAN D. ETA L.: "An Examination of the Interactions Between the Antinociceptive Effects of Morphine and Various -Opioids: The Role of Intrinsic Efficacy and Stimulus Intensity", ANESTH. ANALG., vol. 88, no. 2, February 1999 (1999-02-01), pages 407 - 408 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8309060B2 (en) 2003-08-06 2012-11-13 Grunenthal Gmbh Abuse-proofed dosage form
US8420056B2 (en) 2003-08-06 2013-04-16 Grunenthal Gmbh Abuse-proofed dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form

Also Published As

Publication number Publication date
WO2007005716A2 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
WO2007005716A3 (en) Methods of treatment and compositions for use thereof
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
BRPI1009860A2 (en) compound, use thereof, pharmaceutical composition and method for the therapeutic treatment or prevention of disease in humans or animals
WO2005105107A3 (en) Hormone treatment of multiple sclerosis
WO2005107726A3 (en) Method for the treatment of back pain
ZA200610353B (en) Treatment or prevention of skin conditions or tissue conditions in animals using boryloxypyridylmenthanones
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
EP1848270A4 (en) Transmucosal administration of drug compositions for treating and preventing disorders in animals
WO2007089454A3 (en) Methods for enhancing skin treatments
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
EA201100544A1 (en) APPLICATION OF COMBINATION OF OPIOID AGONIST AND CONJUGATE POLYMER-OPIOID ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL MEDICINE FOR THE TREATMENT AND PREVENTION OF PAIN
WO2007100675A3 (en) Collagenase for treating cellulite
EA200802412A1 (en) THERAPEUTIC COMBINATIONS FOR SUPPORTING MEDICAL CONDITIONS
BRPI0921097A2 (en) pyrazol-3 carboxamide derivative compound with 5-ht2b receptor antagonist activity, preventive or therapeutic agent, pharmaceutical composition and use of the compound or pharmaceutically acceptable salt thereof and method or prevention or treatment.
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2006081127A3 (en) Compositions and therapeutic methods utilizing a combination of a 5-ht1f inhibitor and an nsaid
WO2007135505A8 (en) Veterinary pharmaceutical compositions for the treatment of pain and inflammation
WO2008025790A3 (en) Use of opioid formulations in needle-less drug delivery devices
WO2007057508A3 (en) Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2008105088A1 (en) Agent for treating spinal cord injury
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
WO2006053788A3 (en) Alterations in seborrheic keratoses and their applications
EP2050442A4 (en) Pharmaceutical composition for prevention and/or treatment of bone disease, functional food or health food comprising the composition, and pharmaceutical preparation comprising the composition as active ingredient
EP2801359A3 (en) The use of nicotine for the treatment of sepsis in humans caused by antibiotic

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06786092

Country of ref document: EP

Kind code of ref document: A2